Chimeric antigen receptor (CAR) T-cells on the march: from diffuse large B-cell lymphoma to mantle cell lymphoma

Affiliations

¹ Department of Hematology, CHU de Rennes, Université de Rennes, INSERM U1236, EFS, Rennes, France; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: roch.houot@chu-rennes.fr.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Editorial

Roch Houot et al. Eur J Cancer. 2020 May.

. 2020 May:131:51-52.

doi: 10.1016/j.ejca.2020.03.001. Epub 2020 Apr 10.

¹ Department of Hematology, CHU de Rennes, Université de Rennes, INSERM U1236, EFS, Rennes, France; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: roch.houot@chu-rennes.fr.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

No abstract available

Comment on

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM. Wang M, et al. N Engl J Med. 2020 Apr 2;382(14):1331-1342. doi: 10.1056/NEJMoa1914347. N Engl J Med. 2020. PMID: 32242358 Free PMC article. Clinical Trial.